Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, …

More from the Prohost Portfolio with Our Observations Gilead (GILD) has cash and new products reaching …

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, …

Exelixis Positive Results from IMspire 150 Exelixis (EXEL) announced positive results from IMspire 150; the phase 3 …

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at …

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks Forty-Seven (FTSV) and  IVERIC bio …

Novartis to Acquire The Medicines Company Novartis (NVS) decided to buy The Medicines Company (MDCO) at …

Alnylam Granted FDA Early Approval of GIVLAARI™ for AHP Alnylam’s (ALNY) stock outperformed as its subcutaneous …

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics (PTCT) has positive results from part 2 of …

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis (EXEL) we learned that its …